Investigation of the Effect of BI 1815368 on the Pharmacokinetics of Metformin Following Multiple Oral Administration in Healthy Subjects (an Open-label, Randomised, Two-way Crossover Trial)
Latest Information Update: 28 Jan 2025
At a glance
- Drugs BI 1815368 (Primary) ; Metformin
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 22 Jan 2025 Status changed from active, no longer recruiting to completed.
- 08 Jan 2025 Planned End Date changed from 13 Dec 2024 to 13 Jan 2025.
- 26 Nov 2024 Status changed from not yet recruiting to active, no longer recruiting.